REVEALED: Amph - The Real Truth

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference. Bill Peters, chief financial officer of Amphastar

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002.

The pharmaceutical industry looks well-positioned for long-term growth. Hence, pharma stocks Procaps Group (PROC), Organon (OGN) and Amphastar (AMPH) might be ideal additions to your watchlists for later gains. Read on.

The pharmaceutical industry looks well-positioned for long term growth due to the globalization of the industry, increasing investments to develop life-saving drugs, rise in chronic diseases, and a rapidly aging population. To that end, it could be wise to buy fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD),…

The medical industry is envisioned to remain afloat and thrive in the foreseeable future, thanks to advanced medical discoveries. Therefore, quality medical stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD), and Voyager Therapeutics (VYGR) could be wise portfolio additions now. Read on….

Fears of an impending recession have kept the stock market volatile. Therefore, it could be wise to invest in quality stocks APi Group (APG), Amphastar Pharmaceuticals (AMPH), and Aquestive Therapeutics (AQST), which institutional investors hold significantly. Read on….

Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) posted Q1 earnings of $24.25 million, an increase from Q4 of 22.74%. Sales dropped to $120.37 million, a 0.43% decrease between quarters.

Irrespective of worsening supply chain disruptions due to the Russia-Ukraine war, the pharmaceutical industry is expected to witness stable growth given the rising medical needs of an aging population and rapid advancements in the drug development process. So, amid an apparent resurgence of COVID-19 cases, we think it could be…

The FDA has approved Amphastar Pharmaceuticals Inc's (NASDAQ:AMPH) Abbreviated New Drug Application for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe.  Ganirelix acetate injection is indicated to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.  The FDA determined Amphastar's ganirelix is bioequivalent and therapeutically equivalent to Organon & Co's (NYSE:OGN) Ganirelix…